Qiagen agrees to go private with €10.8B takeover by EQT
The months-long takeover negotiations surrounding Qiagen have reached a swift conclusion after speculation intensified yesterday that a bidding war between EQT and KKR could emerge. Now a decision has already been reached: The German-Dutch diagnostics specialist and EQT Private Equity have agreed on a voluntary public all-cash takeover offer. The offer price is €46.50 per share. This implies an enterprise value of around €10.8 billion, or $12.1 billion, including net debt. The price is 40.3% above the unaffected Xetra closing price on July 8, 2026, before takeover interest from private equity firms was first publicly reported.
The Money Map: Grants, Accelerators, and Funds Every African Agritech Founder Should Know
63 KEY POINTS African agritech founders can access equity-free grants, accelerator programmes, and dedicated funds rangi…
🎥 Earth Rover bets on pulsed light to tackle weeds without chemicals
Robotic weeders are evolving quickly. Some zap their targets with lasers, hot oil or electricity, others target them wit…
Layoffs at Carbon Robotics as firm “realigns costs due to broader economic conditions”
Seattle-based ag robotics firm Carbon Robotics has blamed “broader economic conditions” for an undisclosed number of lay…
Eastman launches biodegradable micropowder for skin care and SPF formulations
Eastman has launched Esmeri SK1N10, a biodegradable micropowder for skin care and SPF applications that aims to balance sustainability with consumer demand for sensorial performance. The release comes amid tightening synthetic ingredient regulations.
Staggered deadlines complicate EU citral compliance for natural beauty brands
The EU’s incoming citral restrictions contain staggered deadlines that could catch out some cosmetics companies. Personal care products containing the same molecule may have to exit shelves a month apart, creating compliance confusion.
Why Founders Are Returning to Agritech for a Second Shot
58 KEY POINTS A growing number of agritech founders are returning for a second attempt after their first venture failed.…
Reservoir Farms expands to Pacific Northwest to accelerate physical AI
Ag robotics specialist Reservoir is opening a new site in Washington’s Yakima Valley as its on-farm community for …
Muna’s oral Alzheimer’s candidate shifts age-associated markers in Phase 1
Why it matters: Alzheimer’s has no cure, and the EU-approved antibodies lecanemab and donanemab only slow decline in selected early-stage patients with confirmed amyloid and no more than one copy of the ApoE4 gene variant, while requiring infusions and monitoring for brain swelling and bleeding. Rather than targeting amyloid deposits, Muna’s pill aims to strengthen microglia, the brain’s immune cells, through TREM2, a receptor whose impaired function raises Alzheimer’s risk.
Arctic Therapeutics raises $21.5M to take autoimmune programs to clinic
Why it matters: With this round, Arctic is backing AT-002 and AT-003, treatments that could address gaps in the care of patients with autoimmune diseases such as uveitis, an eye inflammation that can threaten sight and whose steroid treatment increases the risk of glaucoma or cataracts. Meanwhile, its clinical-stage drugs target acne (AT-004) and dementia (AT-001), starting with HCCAA, a rare, fatal inherited disease that causes brain hemorrhages and dementia.